Navigation Links
STERIS Corporation Announces Quarterly Dividend Increase of 38%

MENTOR, Ohio, May 7 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced that its Board of Directors has authorized a 38% increase in its quarterly dividend to $0.11 per common share. The dividend is payable June 18, 2009 to shareholders of record at the close of business on May 21, 2009.


The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit

This news release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "confidence," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any future dividend payment or other financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation previously disclosed FDA warning letters and government investigations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, and (f) the possibility that anticipated cost savings may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release may adversely impact Company performance, results, or value.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
2. STERIS Corporation Announces Date of Fiscal 2008 Second Quarter Earnings Release and Conference Call
3. STERIS Corporation Announces Fiscal 2008 Second Quarter Results
4. STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call
5. STERIS Corporation Declares Regular Quarterly Dividend
6. STERIS Corporation Announces Fiscal 2008 Third Quarter Results
7. STERIS Corporation Promotes Timothy L. Chapman to Group President of Healthcare
8. STERIS Corporation Announces New $300 Million Share Repurchase Authorization
9. STERIS Corporation Names Michael J. Tokich Chief Financial Officer
10. STERIS Corporation Declares Regular Quarterly Dividend
11. Steris Corporation Announces the Appointment of Two New Directors
Post Your Comments:
(Date:11/25/2015)... ... , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in ... Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers ... for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... more and more widely heralded as a breakthrough for performing hernia repairs. The article ... traditional laparoscopic surgery is that it can greatly reduce the pain that a patient ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
(Date:11/25/2015)... ... 25, 2015 , ... SCOTTSDALE, AZ) - Today, Dr. ... both surgical and non-surgical treatments, announced the expansion of his private practice capabilities ... , Highly trained and nationally recognized for his natural approach, Dr. Todd ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Asia Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise ... the Demand " report to their offering. ... --> Boston scientific and others. ... players including Medtronic, Biotronik, Boston scientific ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
Breaking Medicine Technology: